CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

ATTR-CM is a disease in which harmful proteins build up in the heart, making it harder to pump blood, according to the ...

Cantor Fitzgerald said that while the firm “congratulates” Alnylam Pharmaceuticals (ALNY) on last week’s Amvuttra approval, with the stock ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Food and Drug Administration (FDA) to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a potentially fatal disease of the ...

As Alnylam approaches a potential milestone with its lead product Amvuttra, investors and analysts are closely watching its progress in this rapidly expanding market. Want deeper insights into ...

As Alnylam approaches a potential milestone with its lead product Amvuttra, investors and analysts are closely watching its progress in this rapidly expanding market. Want deeper insights into ALNY’s ...

The sudden rise in the stock price can be attributed to the FDA approval of Alnylam's regulatory filing seeking the label expansion of its lead drug, Amvuttra (vutrisiran), for treating the ...

The optimism from JPMorgan extends beyond Amvuttra to Alnylam's overall platform and pipeline, which the analysts find broad and compelling. They believe these factors contribute to a solid ...